18 April 2023 - What was the added therapeutic benefit of the 50 top selling drugs in Medicare in 2020, as assessed by key non US health technology assessment organisations?

Findings More than half of top selling drugs in Medicare did not receive a moderate or high added therapeutic benefit rating by the national HTA organisation of France, Germany, or Canada; these 27 drugs accounted for $19.3 billion net spending, or 11% of Medicare net prescription drug spending in 2020.

Read JAMA article